Vera Therapeutics is a clinical-stage biotechnology company focused on developing treatments for immunological and inflammatory diseases. Vera's mission is to develop and commercialize transformative new therapies that improve patients' lives. Vera's lead program is atacicept, a fusion protein that is a dual inhibitor of B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which is in development for IgA nephropathy (IgAN), also known as Berger's disease.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/22/21 | $80,000,000 | Series C |
Abingworth Alexandria Venture Investments Fidelity Management & Research Company GV Kleiner Perkins Caufield and Byers Longitude Capital Octagon Capital Sofinnova Ventures Surveyor Capital | undisclosed |
